Đang chuẩn bị liên kết để tải về tài liệu:
Is lower-dose sugammadex a cost-saving strategy for reversal of deep neuromuscular block? Facts and fiction

Sugammadex, a γ-cyclodextrin derivative, belongs to a new class of selective relaxant binding agents. Sugammadex was approved 10-years ago by the European medicines agency and today is used in clinical anesthesia and emergency medicine globally. In this review, indications for neuromuscular block, the challenge of neuromuscular monitoring and the practice of under-dosing of sugammadex as a potential cost-saving strategy are discussed. |